AstraZeneca CEO says Summit drug could drive future cancer combos
AstraZeneca CEO Pascal Soriot told CNBC on Monday that Summit Therapeutics‘ lead drug could help power next-generation cancer…
Stocks making the biggest moves midday: CCL, FICO, BE, IOVA
Here are some of the companies making headlines in midday trading. Carnival — Carnival’s stock rose 12% after…
Stock market news for Sept. 29, 2026
Traders work on the floor of the New York Stock Exchange (NYSE) in New York on Sept. 16,…
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS…
ASCO: Summit Akeso ivonescimab improves survival in Harmoni-6 trial
Piotr Swat | Lightrocket | Getty Images An experimental lung cancer drug from Akeso and Summit Therapeutics reduced…